IgGenix Revenue and Competitors

Location

$35M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • IgGenix's estimated annual revenue is currently $1.4M per year.(i)
  • IgGenix's estimated revenue per employee is $77,500
  • IgGenix's total funding is $35M.

Employee Data

  • IgGenix has 18 Employees.(i)
  • IgGenix grew their employee count by -25% last year.

IgGenix's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Interim Chief Scientific OfficerReveal Email/Phone
3
Scientific Co-FounderReveal Email/Phone
4
EVP, Business Development & OperationsReveal Email/Phone
5
Associate Director DevelopmentReveal Email/Phone
6
Co-founder & Chief Technical OfficerReveal Email/Phone
7
Chief Technical OfficerReveal Email/Phone
8
Chief Scientific OfficerReveal Email/Phone
9
Antibody Engineering ScientistReveal Email/Phone
10
Senior Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is IgGenix?

IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA.

keywords:N/A

$35M

Total Funding

18

Number of Employees

$1.4M

Revenue (est)

-25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

IgGenix News

2022-04-20 - IgGenix Announces Move of Headquarters to Lilly Gateway ...

IgGenix joins 8 other leading biotechnology companies in the South San Francisco Gateway Labs. “The purpose of the Lilly Gateway Labs is to...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.1M18-10%N/A
#2
$2.8M18-10%N/A
#3
$1.5M18-5%N/A
#4
$3.8M200%N/A
#5
$3.1M2025%$0.125M